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Background: In this study, we assessed whether red blood cell distribution width
(RDW) was associated with all-cause mortality in patients on peritoneal dialysis
(PD) and evaluated its prognostic value.
Methods: This study included 136 patients who had RDW levels at PD initiation
from January 2007 to January 2014 at the Presbyterian Medical Center and Seoul St.
Mary's Hospital. We divided these patients into 2 groups (survivors vs. non-
survivors), compared their clinical characteristics, and analyzed the predictors of
survival.
Results: The study included 79 men and 57 women, with a mean age of 54 years
(range, 15e85 years). The mean follow-up duration was 32 months (range, 1e80
months). Of 136 patients, 14 died during the follow-up period. When clinical
characteristics of survivors (n ¼ 122) and nonsurvivors (n ¼ 14) were compared, no
differences were identiﬁed, with the exception of serum albumin, total iron-binding
capacity (TIBC), left ventricular ejection fraction, total leukocyte count, and RDW
value. Survivors had higher serum albumin (3.4 ± 0.5 vs. 3.0 ± 0.5 g/dL, P < 0.001)
and left ventricular ejection fraction (56.8 ± 9.8 vs. 48.7 ± 12.8, P ¼ 0.040) and lower
TIBC (213.4 ± 40.9 vs. 252.8 ± 65.6, P ¼ 0.010), total leukocyte counts (6.9  103/mL
vs. 8.6  103/mL, P ¼ 0.009), and serum RDW values (13.9 ± 1.7 vs. 16.0 ± 1.8,
P < 0.001). Patients with high RDW levels ( 14.8) showed signiﬁcantly higher
all-cause mortality than patients with low RDW levels (< 14.8, P < 0.001).
In multivariate-adjusted Cox analysis, RDW and TIBC at the start of PD were
independent risk predictors for all-cause mortality.
Conclusion: RDW could be an additive predictor for all-cause mortality in patients
on PD.
Copyright © 2016. The Korean Society of Nephrology. Published by Elsevier. This is
an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/)., Department of Internal
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Red blood cell distribution width (RDW) is an index mea-
surement of erythrocyte volume variability and is routinely
reported as a part of a complete blood cell count [1,2]. Elevatedy Elsevier. This is an open access article under the CC BY-NC-ND license
Table 1. Comparison of baseline characteristics between survivors
and nonsurvivors
Survivors
(N ¼ 122)
Nonsurvivors
(N ¼ 14)
P
Age (y) 54.0 ± 12.0 58.0 ± 12.0 0.342
Male 74 (61) 5 (39) 0.301
Duration of dialysis (mo) 34.0 ± 23.0 15.0 ± 21.0 0.007
Diabetes 62 (51) 7 (50) 0.592
Previous CV disease 6 (5) 1 (7) 0.540
RDW (%) 13.9 ± 1.7 16.0 ± 1.8 < 0.001
Hemoglobin (g/dL) 9.0 ± 1.8 9.5 ± 1.4 0.421
Ferritin (ng/mL) 360.4 ± 333.8 571.2 ± 808.9 0.138
Iron (mg/dL) 67.5 ± 31.3 58.5 ± 25.9 0.380
TIBC (mg/dL) 213.4 ± 40.9 252.8 ± 65.6 0.010
Erythropoietin-stimulating
agent
109 (89) 13 (93) 0.260
Total leukocyte
count (103/mL)
6.9 ± 2.2 8.6 ± 3.6 0.009
Platelet (103/mL) 191.0 ± 74.0 227.0 ± 92.0 0.140
C-reactive protein (mg/dL) 1.3 ± 2.3 2.4 ± 4.1 0.142
Intact PTH (pg/mL) 320.3 ± 420.3 296.4 ± 337.6 0.349
Albumin (mg/dL) 3.4 ± 0.5 3.0 ± 0.5 < 0.001
Total cholesterol (mg/dL) 160.0 ± 52.0 166.0 ± 60.0 0.680
Triglyceride (g/dL) 170.0 ± 200.0 136.0 ± 63.0 0.521
Na (mEq/L) 138.3 ± 3.6 136.5 ± 3.3 0.156
CO2 (mEq/L) 21.4 ± 5.4 23.3 ± 3.4 0.192
Echocardiographic data*
LA diameter (mm2) 40.6 ± 11.0 44.6 ± 2.7 0.561
LV ejection fraction 56.8 ± 9.8 48.7 ± 12.8 0.040
E/E0 ratio 13.7 ± 5.6 16.6 ± 9.7 0.213
Data are presented as means ± SD or number (%).
*Echocardiographic data were available in 99 patients.
CV, cardiovascular; LA, left atrium; LV, left ventricular; PTH, parathyroid
hormone; RDW, red blood cell distribution width; TIBC, total iron-
binding capacity.
Sun et al / Clinical signiﬁcance of RDW in PD patients 115RDW reﬂects increased size variations of red blood cells,
which indicates altered erythrocyte life span or dysfunctional
erythrocytes. For a long time, RDW has been regarded as a
useful index to differentiate the etiology of anemia, such
as thalassemia and megaloblastic anemia, as well as iron
deﬁciencyerelated anemia [3].
In recent years, it was observed that high RDW levels were
associated with an increased risk of adverse outcomes in the
general population [4], severe sepsis [5], heart failure [6],
coronary artery disease [7], stroke [8], acute kidney injury
that required renal replacement therapy [9], and kidney
transplant recipients [10]. In addition, it was reported that
high RDW is associated with early failure of arteriovenous
ﬁstula for hemodialysis access [11]. The exact mechanisms
causing elevated RDW in these diverse conditions are un-
known; however, it is assumed to be related to inﬂammatory
processes that might interfere with the process of erythro-
poiesis [12]. A few authors reported that increased RDW is a
predictor of mortality in end-stage renal disease (ESRD)
patients [13,14].
However, there are only a few studies that have investigated
the association between RDW and adverse outcomes in
patients on peritoneal dialysis. Therefore, we investigated the
association between increased RDW and all-cause mortality in
patients on peritoneal dialysis (PD).
Methods
Patient selection
Between 2007 and 2014, 458 patients received PD as a renal
replacement therapy at the Presbyterian Medical Center and
Seoul St. Mary's Hospital. Therefore, 136 patients were included
in this study and were divided into 2 groups: survival (n ¼ 122)
and nonsurvival (n ¼ 14). This study was approved by the
institutional review boards of the Presbyterian Medical Center
and Catholic University of Korea.
Clinical and laboratory information
The patients' baseline demographics as well as clinical and
laboratory data were reviewed at the start of PD. The reference
range for RDW levels in this study was 12.2e14.8%. The primary
end point was all-cause mortality and the secondary end point
was nonfatal cardiovascular (CV) events. CV events were
deﬁned as coronary artery disease (coronary artery bypass
surgery, percutaneous intervention, or myocardial infarction),
heart failure, ventricular arrhythmia, cerebrovascular accidents
(cerebral infarction, transient ischemic attack, or cerebral
hemorrhage), or peripheral arterial disease.
Statistical analysis
All the data are presented as the mean ± standard deviation
unless otherwise speciﬁed. Comparisons of continuous
variables between groups were carried out using the
WilcoxoneManneWhitney test. Comparisons between groups
for categorical variables were carried out using the chi-square
test. KaplaneMeier curves and log-rank tests were used to
describe and compare the event-free survival rates for all-cause
mortality. Prognostic variables for mortality were analyzed by
using the univariate Cox proportional hazards model, andvariables with P < 0.1 in univariate analysis were used in the
multivariate Cox proportional hazards model. The univariate
and multivariate Cox regression analysis results are presented
as hazard ratios and 95% conﬁdence intervals. A P value of
< 0.05 was considered statistically signiﬁcant. Statistical anal-
ysis was carried out using SPSS software, version 21 (IBM cor-
poration, New York, NY, USA).
Results
Baseline characteristics
The study included 79 (58%) men and 57 (42%) women, with
amean age of 54 years (range,15e85 years). Sixty-nine patients
had diabetes. The initial hemoglobin and mean RDW levels
were 8.9 g/dL and 14.2%, respectively. The serum albumin was
3.3 g/dL. One hundred twenty-two patients (90%) received
erythropoiesis-stimulating agents. During the mean follow-up
of 32 months (range, 1e80 months), 14 deaths (9%) and 18
nonfatal CV events (14%) occurred.
Comparison of clinical characteristics between survivors and
nonsurvivors
Survivors had higher serum albumin (3.4 ± 0.5 vs.
3.0 ± 0.5 g/dL, P < 0.001) and left ventricular ejection fraction
(LVEF; 56.8 ± 9.8 vs. 48.7 ± 12.8, P¼ 0.040) and lower total iron-
binding capacity (TIBC; 213.4 ± 40.9 vs. 252.8 ± 65.6, P¼ 0.010),
total leukocyte counts (6.9 103/mL vs. 8.6 103/mL, P¼ 0.009),
and serum RDW values (13.9 ± 1.7 vs. 16.0 ± 1.8, P < 0.001) than
nonsurvivors (Table 1).
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low-RDW groups
According to RDW normal reference in our hospital, patients
with measured RDW values were divided into 2 groups: low-
RDW group (< 14.8) and high-RDW group ( 14.8). When we
compared the clinical characteristics of the low- (n ¼ 94) and
high-RDW (n ¼ 42) groups, no differences were observed, with
the exception of C-reactive protein, TIBC, LVEF, all-cause mor-
tality, and nonfatal CV events (Table 2). While CV mortality was
not different between the 2 groups, the high-RDW group
showed signiﬁcantly lower event-free survival rates for all-
cause mortality and nonfatal CV events than the low-RDW
group (Fig. 1).
Predicting survival in patients on PD
Of the 14 patients who died during the study period, 10
patient deaths were caused by sepsis and 3 were related to CV
events. The causes of sepsis were as follows: 5 were pneu-
monia, 1 was bowel perforation, 1 was encapsulating perito-
neal sclerosis, and 3 were of unknown origin. Univariate
analysis indicated that serum albumin, RDW values, TIBC, C-
reactive protein, total leukocyte count, and LVEF were signif-
icant predictors of mortality in patients on PD. After adjusting
for these factors in a multivariate-adjusted Cox analysis, total
leukocyte counts, serum albumin, and RDW values were the
most important prognostic factors in ESRD patients who
received PD treatment (Table 3). In case of nonfatal CV events,Table 2. Comparison of baseline characteristics between high and
low RDW value
High RDW
(N ¼ 42)
Low RDW
(N ¼ 94)
P
Age (y) 56.0 ± 12.0 53.0 ± 13.0 0.200
Male 26 (63) 53 (56) 0.261
Duration of dialysis (mo) 25.0 ± 20.0 34.0 ± 24.0 0.064
Diabetes 25 (61) 44 (46) 0.153
Previous CV disease 2 (4.8) 5 (5.3) 0.531
Hemoglobin (g/dL) 8.9 ± 1.6 9.1 ± 1.9 0.731
Ferritin (ng/mL) 418.0 ± 546.0 368.7 ± 330.5 0.632
Iron (mg/dL) 63.3 ± 27.3 68.4 ± 32.2 0.491
TIBC (mg/dL) 229.3 ± 54.3 211.3 ± 39.4 0.091
Erythropoietin-stimulating
agent
39 (93) 84 (88) 0.230
Total leukocyte
count (103/mL)
7.5 ± 2.4 7.0 ± 2.4 0.231
Platelet (103/mL) 207.0 ± 85.0 188.0 ± 73.0 0.225
C-reactive protein 2.2 ± 3.6 1.1 ± 0.9 0.027
Intact PTH (pg/mL) 281.2 ± 255.1 337.2 ± 320.2 0.051
Albumin (g/dL) 3.1 ± 0.5 3.3 ± 0.5 0.050
Na (mEq/L) 138.7 ± 3.9 137.9 ± 3.5 0.271
CO2 (mEq/L) 21.8 ± 4.2 21.5 ± 5.7 0.832
Echocardiographic data*
LA diameter (mm2) 38.9 ± 13.2 42.6 ± 11.0 0.431
LV ejection fraction 54.5 ± 11.8 56.8 ± 10.4 0.041
E/E0 ratio 16.1 ± 7.2 13.0 ± 7.1 0.102
Nonfatal cardiovascular
event
10 (25) 8 (8) 0.021
Fatal cardiovascular event 1 (2.43) 2 (2.22) 0.532
Death 10 (24.4) 5 (5.6) < 0.001
Data are presented as means ± SD or number (%).
*Echocardiographic data were available in 99 patients.
CV, cardiovascular; LA, left atrium; LV, left ventricular; PTH, parathyroid
hormone; RDW, red blood cell distribution width; TIBC, total iron-
binding capacity.age and presence of diabetes were the signiﬁcant predictors
(Table 4).
Discussion
RDW, routinely reported as part of a complete blood cell
count, is a simple laboratory test that is used to evaluate vari-
ability in the size and form of red blood cells [1,2]. Several studies
have recently shown that elevated RDW is a predictor of
morbidityandmortality inCVdiseases, such as acute and chronic
congestive heart failure, acute myocardial infarction, pulmonary
hypertension, peripheral artery disease, and stroke [6e8,15]. In
addition, high RDW has emerged as a risk factor in clinical
nephrology, including hemodialysis patients and patients with
acute kidney injuries that require continuous renal replacement
therapy. Yoon et al [13] reported that a progressive rise in RDW
predicts mortality and CV events in ESRD. In our study, the RDW
value was also higher in nonsurvivors than in survivors, and it
was an independent risk predictor for all-cause mortality.
The US Renal Data System (USRDS) and ANZDATA Registry
reported that the most common cause of death is cardiovas-
cular disease, in which infectious disease was the second
leading cause [16e18]. However, Choi et al [19] reported that
infection was the most common cause of death in Korean pa-
tients on PD. Of the 14 patients that died during this study
period,10 of themwere attributable to infectious diseases, such
as sepsis. It has also been reported that RDW is associated with
inﬂammatory and infectious conditions. Ku et al [20] and Braun
et al [21] reported that RDW is an independent predictor of
mortality among patients with gram-negative bacteremia and
community-acquired pneumonia. The 2 primary causes of
death in PD patients in this study were infection and
CV disease, and we believe that RDW could be an additive
predictor for all-cause mortality in patients on PD.
Previous literature has reported that RDW is a predictor of
CV mortality in various populations [22]. However, only a few
reports have discussed the relevance of RDW and CV mortality
and morbidity in ESRD patients [7,8]. Recently, Yoon et al [13]
reported that a progressive rise in RDW predicts mortality
and CV events in ESRD patients. Peng et al [23] also reported
that a high baseline RDW value was associated with CV mor-
tality in incidental PD patients. However, high RDW was not
associated with CV mortality in our study. We believe that this
ﬁnding might be due to different causes of death such as
infection in our study. In addition, although patients with high
RDW levels showed signiﬁcantly more frequent nonfatal CV
events than patients with low RDW levels, the RDW was not a
signiﬁcant predictor in the present study. Therefore, to clarify
the association between RDW and CV mortality, large pro-
spective controlled studies are needed.
Although the mechanism underlying the association be-
tween higher RDW and adverse outcomes in PD patients is not
completely understood, several mechanisms can be postulated.
First, increasing RDW may indicate impaired iron metabolism
and is assumed to be related to inﬂammation which might
interfere with the process of erythropoiesis [12,24]. Impaired
iron metabolism is reported to be associated with heart failure
[25]. In the present study, TIBC was higher in the high-RDW
group than in the low-RDW group and was the independent
risk predictor for all-cause mortality. In addition, inﬂammatory
response plays a critical role in the development and progres-
sion of heart failure [26,27] and inhibits erythrocytematuration
Table 3. Cox proportional hazards analysis for all-cause mortality
Univariate Multivariate
HR (95% CI) P HR (95% CI) P
RDW (per 1% increase) 1.687 (1.342e2.100) < 0.001 2.908 (1.346e6.284) 0.007
TIBC (mg/dL) 1.016 (1.003e1.028) 0.014 1.019 (1.002e1.037) 0.032
Albumin (g/dL) 0.343 (0.147e0.803) 0.014 0.396 (0.013e12.473) 0.609
CRP (mg/dL) 1.148 (1.000e1.317) 0.050 1.153 (0.864e1.539) 0.333
TLC (103/mL) 1.244 (1.044e1.483) 0.015 0.958 (0.676e1.358) 0.809
LVEF (%) 0.946 (0.896e0.998) 0.041 0.958 (0.817e1.013) 0.809
CI, conﬁdence interval; CRP, C-reactive protein; HR, hazard ratio; LVEF, left ventricular ejection fraction; RDW, red blood cell distribution width;
TIBC, total iron-binding capacity; TLC, total leukocyte count.
Table 4. Cox proportional hazards analysis for nonfatal CV events
Univariate Multivariate
HR (95% CI) P HR (95% CI) P
RDW (per 1% increase) 1.513 (1.161e1.971) 0.002 1.464 (0.870e2.464) 0.152
Age 1.122 (1.061e1.187) < 0.001 1.099 (1.005e1.201) 0.038
Presence of diabetes 9.256 (1.176e72.86) 0.035 10.428 (1.243e87.482) 0.031
LVEF (%) 0.983 (0.931e1.038) 0.530 0.111 (0.880e1.013) 0.111
CI, conﬁdence interval; CV, cardiovascular; HR, hazard ratio; LVEF, left ventricular ejection fraction; RDW, red blood cell distribution width.
Figure 1. KaplaneMeier plots for all-cause mortality and nonfatal CV events. Patients with high RDW levels ( 14.8) showed signiﬁcantly higher all-
cause mortality and nonfatal CV events than patients with low RDW levels.
CV, cardiovascular; RDW, red blood cell distribution width.
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eral circulation, thereby increasing RDW [28]. Therefore, RDW
may bridge the relationship between inﬂammation and poorer
heart failure prognosis. In this study, C-reactive protein, which
is regarded as an inﬂammatory marker, was also higher in the
high-RDW group than in the low-RDW group. We think that
such ﬁndings might contribute to the lower event-free survival
rate for nonfatal CV events and all-cause mortality in the high-
RDW group.
Second, a mechanism that could be involved in such a pro-
cess is the release of cytokines in response to inﬂammatory
stress. These cytokines might block the activity of erythropoi-
etin, inhibit erythrocyte maturation, and cause production of
ineffective red blood cells and elevated RDW [12]. The expan-
sion of proinﬂammatory cytokines may increase susceptibilityto infections [29]. In addition, Duranay et al [30] reported that
oxidative stress seems to increase peritonitis in continuous
ambulatory peritoneal dialysis patients. In our study, no pa-
tients expired because of PD-associated peritonitis; however,
infection was an important cause of death. Four patients of 10
who expired because of infection experienced sepsis because of
pneumonia within 6 months after starting PD.
Our study has some limitations. First, this is a retrospective
study and the study population comprised only Asian people.
Second, despite a single measurement of RDW levels that could
have reﬂected acute changes in RDW induced by blood loss or
hemolysis, we did not evaluate ﬂuctuations in RDW levels and
thus could not account for possible variation over time.
In our study, RDW, albumin, and total leukocyte counts
when patients started PD were associated with the incidence of
Kidney Res Clin Pract 35 (2016) 114e118118mortality. RDW is a widely available and inexpensive test per-
formed as part of the complete blood cell count. Therefore,
measuring the RDW at initiation of PD is helpful for predicting
all-cause mortality in patients on PD.
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